SCHEMBL3584957

SCHEMBL3584957

COc1ccc(CCCN(C)C)c(N)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 3/20 0.56
HTR2A P28223 3/20 0.46
AOC3 Q16853 1/20 0.45
SLC6A2 P23975 2/20 0.45
SLC6A3 Q01959 2/20 0.45
HTR6 P50406 4/20 0.44
HTR2C P28335 2/20 0.44
HTR2B P41595 2/20 0.44
HTR3E A5X5Y0 1/20 0.44
HTR3B O95264 1/20 0.44
CYP1A2 P05177 1/20 0.44
HTR1A P08908 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
HTR1D P28221 1/20 0.44
HTR1B P28222 1/20 0.44
HTR1E P28566 1/20 0.44
HTR1F P30939 1/20 0.44
HTR7 P34969 1/20 0.44
HTR3A P46098 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22897755 0.81 ALDH1A1 (0.47) MTNR1AMEN1ALDH1A1MAPTTHRB
SCHEMBL2723478 0.80 ALDH1A1 (0.49) CYP2D6MTNR1AMEN1ALDH1A1MAPT
SCHEMBL10044940 0.78 SLC6A4 (0.53) SLC6A4HTR2AAOC3HTR6HTR2C
SCHEMBL3816078 0.78 ALDH1A1 (0.50) SLC6A4AOC3SLC6A2SLC6A3MEN1
SCHEMBL5217973 0.78 TAAR1 (0.62) HTR2AHTR6HTR2CCYP1A2HTR1A
SCHEMBL3575875 0.77 ALDH1A1 (0.46) SLC6A4SLC6A2SLC6A3MTNR1AMEN1
SCHEMBL13349450 0.77 SLC6A4 (0.52) SLC6A4HTR2AAOC3HTR6HTR2C
SCHEMBL3579691 0.76 PTGS2 (0.51) MTNR1AMEN1ALDH1A1MAPTTHRB
SCHEMBL3580131 0.76 ALDH1A1 (0.48) SLC6A4AOC3SLC6A2SLC6A3MEN1
SCHEMBL3579011 0.76 ALDH1A1 (0.52) SLC6A4SLC6A2SLC6A3CYP2D6MTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2118076-B1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO SA (CH) 2019-09-04 EP disclosed
EP-2118076-B1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO SA (CH) 2019-09-04 EP disclosed
US-8614215-B2 Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) MERCK SERONO SA (CH) 2013-12-24 US disclosed
US-20100137308-A1 Quinoxaline Compounds and Use Thereof MERCK SERONO SA (CH) 2010-06-03 US disclosed
US-20100137308-A1 Quinoxaline Compounds and Use Thereof MERCK SERONO SA (CH) 2010-06-03 US disclosed
US-20100137308-A1 Quinoxaline Compounds and Use Thereof MERCK SERONO SA (CH) 2010-06-03 US disclosed
EP-2118076-A1 QUINOXALINE COMPOUNDS AND USE THEREOF Merck Serono S.A. (CH) 2009-11-18 EP disclosed
WO-2008101979-A1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO S.A. (CH) 2008-08-28 WO disclosed
WO-2008101979-A1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO S.A. (CH) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137308-A1 Quinoxaline Compounds and Use Thereof PFKP, PDXK, PF4 SLC6A4 866/4885HTR2A 2041/4885AOC3 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.